BNP (1-32), human (CAS 114471-18-0)

BNP (1-32), human, is a biologically active peptide hormone belonging to the natriuretic peptide family. Research on BNP (1-32), human, has predominantly centered on its physiological role in cardiovascular homeostasis and its potential applications in cardiovascular research. This peptide hormone is primarily synthesized and released by the ventricular myocardium in response to increased cardiac wall stress and volume overload. Mechanistically, BNP (1-32), human, exerts its effects by binding to and activating the natriuretic peptide receptor-A (NPR-A), a membrane-bound guanylyl cyclase receptor. Upon activation, NPR-A catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), leading to intracellular signaling cascades that promote vasodilation, natriuresis, and diuresis. In research settings, BNP (1-32), human, has been utilized to investigate the physiological mechanisms underlying cardiovascular regulation, including blood pressure control, fluid balance, and cardiac remodeling. Furthermore, this peptide hormone has been instrumental in elucidating the pathophysiology of various cardiovascular disorders, such as heart failure, hypertension, and myocardial infarction, by providing insights into the compensatory mechanisms activated in response to cardiac dysfunction. Additionally, BNP (1-32), human, has been employed in experimental models to explore novel strategies targeting the natriuretic peptide system for the management of cardiovascular diseases. Overall, BNP (1-32), human, serves as a valuable tool in cardiovascular research, offering insights into the complex interplay of peptides and receptors in cardiovascular physiology and pathophysiology.